Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high ...

Viz.ai is to enter a multi-year collaboration with Sanofi and Regeneron aimed at deploying and assessing an AI-powered ...

RK Asset Management boosted its stake in Regeneron Pharmaceuticals by 25.8%, bringing its total to 12,563 shares worth $7.97 ...

Federal jurors in Delaware found that Amgen violated antitrust laws by bundling its cholesterol treatment with substantial ...

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Viz.ai's recent partnership with Sanofi and Regeneron Pharmaceuticals (NasdaqGS:REGN) brings AI technology to aid in the management of COPD patients, enhancing the healthcare process. Throughout the ...

Fintel reports that on May 30, 2025, Wells Fargo downgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from ...

Federal jurors in Delaware found that Amgen violated antitrust laws by bundling its cholesterol treatment with substantial ...

Viz.ai is to enter a multi-year collaboration with Sanofi and Regeneron aimed at deploying and assessing an AI-powered workflow solution for improving the management of chronic obstructive ...

Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...

Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million ...